此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

用于胃出口梗阻的 AXIOS™ 胃肠造口术 IDE

2026年11月3日 更新者:Boston Scientific Corporation

内镜超声引导下金属支架腔内造口术治疗恶性不可切除疾病引起的胃出口梗阻的前瞻性多中心、单臂研究

To investigate the safety and technical success of EUS-guided gastroenterostomy (EUS-GE) using the AXIOSTM lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm.

研究概览

详细说明

The study is a prospective multi-center, single -arm study with treatment of up to 67 subjects at up to 10 clinical centers. Subjects who meet all eligibility criteria will receive the AXIOS stent and up to 12 months follow-up.

研究类型

介入性

注册 (估计的)

67

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200433
        • Shanghai Changhai Hospital
      • Montreal、加拿大、H3Z 2E9
        • McGill University Health Care
      • Hyderabad、印度
        • Asian Institute of Gastroenterology
      • São Paulo、巴西、01246-092
        • Instituto do Cancer do Estado de Sao Paulo
      • Leuven、比利时
        • UZ Leuven
    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • Brigham and Women's Hospital
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic
    • New York
      • New York、New York、美国、10065
        • New York Presbyterian/ Weill Cornell Medical Center
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15213
        • University of Pittsburg Medical Center
    • Washington
      • Seattle、Washington、美国、98101
        • Virginia Mason Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Gastric outlet obstruction from unresectable malignant neoplasm
  2. Eligible for endoscopic intervention
  3. GOOS of 0 or 1 0 - no oral intake 1 - liquids only 2 - soft solids only 3 - low-residue or full diet
  4. 18 years of age or older
  5. Willing and able to comply with the study procedures or legally authorized representative (LAR) must provide written informed consent form (ICF) to participate in the study
  6. The distance between the gastric lumen and jejunal lumen must be no more than 1.0 cm

Exclusion Criteria:

  1. Patients with baseline ECOG > 2 and/or Karnofsky Performance score < 30
  2. Gastric cancer or any malignant infiltration precluding a cancer free puncture site of the AXIOSTM stent
  3. Abnormal coagulation INR > 1.5 and not correctable (per the discretion of the physician) or who require continuous complete anticoagulation, and/or any underlying condition associated with high risk of bleeding
  4. Altered anatomy of the upper gastrointestinal tract due to surgery of esophagus, stomach and duodenum that might preclude endoscopic gastroenterostomy
  5. Multiple-level bowel obstruction downstream from the intended location of the EUS-guided bypass confirmed by radiography such as small bowel series or computed tomography
  6. Presence of intraperitoneal fat between the gastric lumen and jejunal lumen estimated to be larger than 1.0 cm at the proposed site of AXIOSTM stent insertion
  7. Gastric varices located within a two-centimeter radius of the device insertion location on the gastric wall
  8. Ascites Grade ≥ 2 confirmed by cross-sectional imaging
  9. Vessels located within a two-centimeter radius of the device insertion location
  10. History of multiple abdominal surgeries and/or evidence of small bowel adhesions
  11. Allergic to any of the device materials
  12. Contraindications to use of electrical devices
  13. Pregnancy
  14. Prisoners and other vulnerable populations

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:AXIOS(TM) Stent and Electrocautery Enhanced Delivery System

Patients who meet all the inclusion criteria and none of the exclusion criteria will have a EUS-guided gastroenterostomy (EUS-GE) using the AXIOS(TM) lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm

Patients who meet all the inclusion criteria and none of the exclusion criteria will have a EUS-guided gastroenterostomy (EUS-GE) using the AXIOS(TM) lumen-apposing Metal Stent for the management of symptoms associated with gastric outlet obstruction from malignant unresectable neoplasm

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Serious Adverse Events
大体时间:Through study completion, an average of 1 year

The proportion of subjects with one or more AXIOS stent related or AXIOS endoscopic and/or study procedure related serious adverse events through 30 days post stent placement.

Through study completion, an average of 1 year
Technical Success
大体时间:During the procedure

The proportion of subjects that demonstrate technical Successful stent placement, defined as transmural placement of the AXIOS stent with confirmed stent patency by visualization of the contralateral wall of the small bowel through the AXIOS stent lumen. Visualization of blue dye in the gastric lumen or injection of contrast to confirm continuity of the gastroenteric lumen, may be used to provide supplemental confirmation of intended stent placement. Note: Visualization of blue dye in the gastric lumen or injection of contrast to confirm continuity of the gastroenteric lumen, may be used to provide supplemental confirmation of intended stent placement.

During the procedure
Primary Effectiveness Endpoint
大体时间:through 14 days after procedure

Clinical Success defined as improvement of Gastric Outlet Obstruction Score (GOOS)by 1 point from baseline to any point during 14 days after AXIOS stent placement and GOOS remaining at 1 or more without the need for reintervention due to loss of stent function at 30 days post-index procedure or death, whichever comes first.

through 14 days after procedure

其他结果措施

结果测量
措施说明
大体时间
支架置入后恢复口服摄入的时间。
大体时间:手术后立即
手术后立即
AXIOSTM 支架放置后开始或恢复化疗的时间(如适用)
大体时间:手术后立即
手术后立即
生活质量评分(SF-12 问卷)从基线到 30 天、3 个月、6 个月和 12 个月的变化
大体时间:通过学习完成,平均1年
通过学习完成,平均1年
Clinical success over time defined as improvement of GOOS by 1 point from baseline at any time during 14 days after AXIOS stent placement and GOOS remaining at 1 or more. This endpoint will be evaluated at 3 months, 6 months, and 12 months
大体时间:Through study completion, an average of 1 year

A patient undergoing reintervention for GOO is considered a failure of clinical success

Through study completion, an average of 1 year
Incidence of Device Deficiencies
大体时间:Immediately after the procedure

Including but not limited to stent migration/misplacement, stent occlusion, leakage at site of stent placement.

Immediately after the procedure
Incidence of Reintervention for GOO
大体时间:Immediately after the procedure

defined as need for repeat treatment for persistent or recurrent GOO symptoms

Immediately after the procedure

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Shayan Irani, MBBS, MD、Virginia Mason Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年2月11日

初级完成 (估计的)

2027年9月1日

研究完成 (估计的)

2027年9月1日

研究注册日期

首次提交

2023年12月4日

首先提交符合 QC 标准的

2023年12月15日

首次发布 (实际的)

2023年12月18日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅